A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation… (NCT07382167) | Clinical Trial Compass
RecruitingPhase 3
A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults
United States692 participantsStarted 2026-01-13
Plain-language summary
This is a 26-week, multi-center, randomized, double-blind, placebo-controlled study with a 4-week treatment-free Safety Follow-up period to assess the safety and efficacy of tenapanor (5 mg, 25mg, and 50 mg) in adult patients with Chronic Idiopathic Constipation (CIC) when administered twice daily for 26 consecutive weeks.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patients ≥18 to ≤80 years old at the Screening visit (Visit 1).
✓. Meet the Rome IV Diagnostic Criteria for functional constipation.
✓. Females of non-childbearing potential, or agree to the use of an acceptable means of contraception for up to 30 days following the last dose of study medication.
✓. Males must agree to use an appropriate method of barrier contraception or have documented surgical sterilization.
✓. Meets the entry criteria assessed during the Screening period.
✓. Ability to understand and provide input on the assessments in the eDiary.
✓. Provide written informed consent before the initiation of any study-specific procedures.
✓. Must agree to have daily access to eDiary via a computer, tablet or smart phone
Exclusion criteria
✕. Loose or watery stool in the absence of any medication that is known to affect stool consistency for \>25% of bowel movements (BMs) during the 3 months prior to the Screening visit
✕. Fecal impaction within 6 months prior to the Screening visit
✕. Unexplained and clinically significant alarm symptoms.
✕. Functional diarrhea as defined by Rome IV criteria